Corcept Therapeutics Stock Forecast for 2023 - 2025 - 2030

Updated on 12/07/2023

Stock Rating
16
Price Target
$36.00
Consensus
Outperform
Upside
33.14%
Analysts
4
Stock Rating
16
Upside
33.14%
Analysts
4
Price Target
$36.00

Corcept Therapeutics Stock Forecast and Price Target

If Corcept Therapeutics's stock price reached the average yearlong target of $36.00 given by four well-known analysts in recent months, there would be a potential upside of approximately 33.14% from its last closing price in December, 2023. This potential increase is based on a high estimate of $50.00 and a low estimate of $27.00. If you are interested in CORT stock, it is important to also consider its competitors.

$36.00

33.14% Upside

Outperform
Outperform

Corcept Therapeutics Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, Corcept Therapeutics's Price has decreased by 20.18%, going from $19.05 to $15.21. For next year, analysts predict Fair Value of $16.08, which would mean an increase of 5.75%. Over the next eight years, experts predict that Corcept Therapeutics's Fair Value will grow at a rate of 504.60%.

2023 Fair Value Forecast
$16.08
2024 Fair Value Forecast
$16.26
2025 Fair Value Forecast
$21.85
2026 Fair Value Forecast
$31.99
2027 Fair Value Forecast
$44.40
2028 Fair Value Forecast
$55.41
2029 Fair Value Forecast
$78.83
2030 Fair Value Forecast
$91.94

Corcept Therapeutics Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Corcept Therapeutics's Revenue has grown by 31.12%, rising from $306.49M to $401.86M. For next year, analysts predict Revenue of $474.81M, which would mean an increase of 18.15%. Over the next eight years, experts predict that Corcept Therapeutics's Revenue will grow at a rate of 244.39%.

2023 Rev Forecast
$0.47B
2024 Rev Forecast
$0.54B
2025 Rev Forecast
$0.59B
2026 Rev Forecast
$0.70B
2027 Rev Forecast
$0.81B
2028 Rev Forecast
$0.96B
2029 Rev Forecast
$1.21B
2030 Rev Forecast
$1.38B

Corcept Therapeutics Dividend per Share Forecast for 2023 - 2025 - 2030

Corcept Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, Corcept Therapeutics's Free Cash Flow has decreased from $135.03M to $119.91M – a 11.20% drop! In the next year, analysts believe that Free Cash Flow will reach $163.31M – an increase of 36.19%. For the next eight years, the forecast is for Free Cash Flow to grow by 32.98%.

2023 FCF Forecast
$0.16B
2024 FCF Forecast
$0.16B
2025 FCF Forecast
$0.17B
2026 FCF Forecast
$0.15B
2027 FCF Forecast
$0.16B
2028 FCF Forecast
$0.16B
2029 FCF Forecast
$0.16B
2030 FCF Forecast
$0.16B

Corcept Therapeutics Net Income Forecast for 2023 - 2025 - 2030

Corcept Therapeutics's Net Income has grown In the last three years, rising from $94.18M to $101.42M – a growth of 7.69%. In the next year, analysts believe that Net Income will reach $104.66M – an increase of 3.19%. For the next eight years, experts predict that Corcept Therapeutics's Net Income will grow at a rate of 608.34%.

2023 NI Forecast
$0.10B
2024 NI Forecast
$0.10B
2025 NI Forecast
$0.13B
2026 NI Forecast
$0.20B
2027 NI Forecast
$0.32B
2028 NI Forecast
$0.43B
2029 NI Forecast
$0.61B
2030 NI Forecast
$0.72B

Corcept Therapeutics EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Corcept Therapeutics's EBITDA has grown by 0.99%, rising from $112.31M to $113.42M. According to the 1 analysts polled, in the next year, Corcept Therapeutics's EBITDA will fall by 10.33%, reaching $101.70M. Over the next eight years, experts believe that Corcept Therapeutics's EBITDA will grow at a rate of 136.12%.

2023 EBITDA Forecast
$0.10B
2024 EBITDA Forecast
$0.14B
2025 EBITDA Forecast
$0.22B
2026 EBITDA Forecast
$0.29B
2027 EBITDA Forecast
$0.35B
2028 EBITDA Forecast
$0.26B
2029 EBITDA Forecast
$0.25B
2030 EBITDA Forecast
$0.27B

Corcept Therapeutics EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Corcept Therapeutics's EBIT has grown, moving from $111.61M to $112.63M – an increase of 0.91%. For the next year, 5 analysts project Corcept Therapeutics's EBIT to drop by 3.92%, reaching $108.22M. Looking ahead to eight years, experts forecast that EBIT will grow by 668.26%.

2023 EBIT Forecast
$0.11B
2024 EBIT Forecast
$0.13B
2025 EBIT Forecast
$0.23B
2026 EBIT Forecast
$0.30B
2027 EBIT Forecast
$0.38B
2028 EBIT Forecast
$0.49B
2029 EBIT Forecast
$0.73B
2030 EBIT Forecast
$0.87B

Corcept Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, Corcept Therapeutics's EPS has decreased by 20.18%, going from $1.09 to $0.87. For next year, analysts predict EPS of $0.92, which would mean an increase of 5.75%. Over the next eight years, experts predict that Corcept Therapeutics's EPS will grow at a rate of 504.60%.

2023 EPS Forecast
$0.92
2024 EPS Forecast
$0.93
2025 EPS Forecast
$1.25
2026 EPS Forecast
$1.83
2027 EPS Forecast
$2.54
2028 EPS Forecast
$3.17
2029 EPS Forecast
$4.51
2030 EPS Forecast
$5.26